Published in Pharm Res on August 01, 1994
Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun (2000) 1.35
Trimethyl chitosan and its applications in drug delivery. J Mater Sci Mater Med (2008) 1.02
Microencapsulation of hemoglobin in chitosan-coated alginate microspheres prepared by emulsification/internal gelation. AAPS J (2006) 0.97
Chitosan nanoparticle-based neuronal membrane sealing and neuroprotection following acrolein-induced cell injury. J Biol Eng (2010) 0.96
Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int J Nanomedicine (2012) 0.96
Absorption enhancers for nasal drug delivery. Clin Pharmacokinet (2003) 0.95
Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. Curr Pharm Des (2010) 0.94
Oral Administration of Shark Type II Collagen Suppresses Complete Freund's Adjuvant-Induced Rheumatoid Arthritis in Rats. Pharmaceuticals (Basel) (2012) 0.89
Effect of various absorption enhancers based on tight junctions on the intestinal absorption of forsythoside A in Shuang-Huang-Lian, application to its antivirus activity. Pharmacogn Mag (2014) 0.83
Efficient mucosal delivery of optical contrast agents using imidazole-modified chitosan. J Biomed Opt (2010) 0.83
Methylated N-(4-N,N-dimethylaminobenzyl) chitosan, a novel chitosan derivative, enhances paracellular permeability across intestinal epithelial cells (Caco-2). AAPS PharmSciTech (2008) 0.82
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses (2012) 0.82
Alginate nanoparticles as a promising adjuvant and vaccine delivery system. Indian J Pharm Sci (2013) 0.82
Feasibility study of chitosan as intravitreous tamponade material. Graefes Arch Clin Exp Ophthalmol (2008) 0.81
The biocompatible polysaccharide chitosan enhances the oral tolerance to type II collagen. Clin Exp Immunol (2009) 0.81
Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci (2009) 0.81
Engineered nanoparticulate drug delivery systems: the next frontier for oral administration? AAPS J (2012) 0.80
Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses. Allergy Asthma Clin Immunol (2008) 0.80
Biopolymeric nanoparticles. Sci Technol Adv Mater (2010) 0.78
Surface thermodynamics of mucoadhesive dry powder formulation of zolmitriptan. AAPS PharmSciTech (2011) 0.78
Cationic polybutyl cyanoacrylate nanoparticles for DNA delivery. J Biomed Biotechnol (2009) 0.78
Pharmacokinetics study of bio-adhesive tablet of Panax notoginseng saponins. Int Arch Med (2011) 0.78
Correlating physicochemical properties of boronic Acid-chitosan conjugates to glucose adsorption sensitivity. Pharmaceutics (2012) 0.77
Correlation of SEC/MALLS with ultracentrifuge and viscometric data for chitosans. Eur Biophys J (2003) 0.76
Dense chitosan surgical membranes produced by a coincident compression-dehydration process. J Biomater Sci Polym Ed (2012) 0.75
New methodologies to characterize the effectiveness of the gene transfer mediated by DNA-chitosan nanoparticles. Int J Nanomedicine (2008) 0.75
Prolonged hypocalcemic effect by pulmonary delivery of calcitonin loaded poly(methyl vinyl ether maleic acid) bioadhesive nanoparticles. Biomed Res Int (2014) 0.75
Effect of Quaternary Ammonium Carboxymethylchitosan on Release Rate In-vitro of Aspirin Sustained-release Matrix Tablets. Iran J Pharm Res (2013) 0.75
Chitosan impregnation with biologically active tryaryl imidazoles in supercritical carbon dioxide. J Mater Sci Mater Med (2016) 0.75
Transit of pharmaceutical dosage forms through the small intestine. Gut (1986) 2.35
PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release (1999) 2.08
Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev (2001) 1.87
Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res (1994) 1.61
Evaluation of impotence in older men. West J Med (1985) 1.54
The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res (1993) 1.53
Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun (1991) 1.50
Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst (1987) 1.42
Heavy metals in some Asian medicines and cosmetics. Public Health (1979) 1.42
Physicochemical properties of parenteral fat emulsions containing 20% triglyceride; Intralipid and Ivelip. J Clin Pharm Ther (1993) 1.40
Automated conductimetric titrimeter: use in studying ionic solute-solute interactions. J Pharm Sci (1975) 1.39
Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res (1994) 1.37
Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm (1999) 1.30
Biodegradable microparticles as controlled release antigen delivery systems. Immunology (1991) 1.24
Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit Rev Ther Drug Carrier Syst (1994) 1.21
Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res (1991) 1.20
Chitosan microspheres prepared by spray drying. Int J Pharm (1999) 1.20
Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release (2001) 1.20
Microparticles as potentially orally active immunological adjuvants. Vaccine (1989) 1.19
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 1.19
The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett (1992) 1.17
Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab (1990) 1.16
Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes (Lond) (2011) 1.14
Compliance in medication by Asian immigrants. Nurs Times (1979) 1.13
Lead poisoning and traditional practices: the consequences for world health. A study in Kuwait. Public Health (1981) 1.13
Transport of nanoparticles across the rat nasal mucosa. J Drug Target (2001) 1.11
Morphine kinetics after diamorphine infusion in premature neonates. Br J Clin Pharmacol (1991) 1.09
Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res (1997) 1.08
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta (1993) 1.08
Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target (2001) 1.07
Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target (1993) 1.07
Epi-fluorescence microscopy and image analysis used to measure diffusion coefficients in gel systems. J Pharm Pharmacol (1992) 1.06
Controlled release microparticles for vaccine development. Vaccine (1991) 1.06
Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm (2000) 1.06
The role of gamma-scintigraphy in oral drug delivery. Adv Drug Deliv Rev (2001) 1.04
An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta (1993) 1.04
Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J Pharm Pharmacol (1984) 1.03
Targeting of drugs and vaccines to the gut. Pharmacol Ther (1995) 1.02
Diamorphine infusion in the preterm neonate. Arch Dis Child (1991) 1.02
Techniques for the measurement of the rheological properties of sputum. Bull Physiopathol Respir (Nancy) (1973) 1.02
The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett (1984) 1.00
Intranasal delivery of morphine. J Pharmacol Exp Ther (2002) 0.99
Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine (1995) 0.98
Structure and mucoadhesion of mussel glue protein in dilute solution. Biochemistry (1998) 0.98
The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release (1998) 0.97
Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharm Res (1997) 0.97
Sustained release chitosan microspheres prepared by novel spray drying methods. J Microencapsul (1999) 0.97
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. J Med Chem (1996) 0.96
Scientific principles in design of drug dosage formulations. Br Med J (1972) 0.96
Sugar cross-linked gelatin for controlled release: microspheres and disks. Biomaterials (1998) 0.96
Physical properties and stability of two emulsion formulations of propofol. Int J Pharm (2001) 0.95
Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm (2001) 0.95
The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol (1984) 0.93
In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy. Pharm Res (1992) 0.93
Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol (1988) 0.93
Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett (1994) 0.92
Characterization of colonic transit of nondisintegrating tablets in healthy subjects. Dig Dis Sci (1993) 0.92
The rheological properties of sputum. Biorheology (1969) 0.92
The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine (1999) 0.92
Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release (1999) 0.92
Preparation of surface-modified albumin nanospheres. Biomaterials (1997) 0.91
Transdermal delivery of theophylline to premature infants using a hydrogel disc system. Br J Clin Pharmacol (1990) 0.91
Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc (1988) 0.91
Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Control Release (2001) 0.91
The effect of the nasal cycle on mucociliary clearance. Clin Otolaryngol Allied Sci (2001) 0.90
The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. Life Sci (1987) 0.89
Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm (2001) 0.89
Albumin microspheres for intra-articular drug delivery: investigation of their retention in normal and arthritic knee joints of rabbits. J Pharm Pharmacol (1987) 0.89
Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers. FEBS Lett (1997) 0.88
Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. J Pharm Sci (1983) 0.88
Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine (1993) 0.88
Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J (2000) 0.88
Morphology of Golgi-impregnated neurons in hyperstriatum ventralis, pars caudalis in adult male and female canaries. J Comp Neurol (1989) 0.87
Preparation of sterically stabilized human serum albumin nanospheres using a novel Dextranox-MPEG crosslinking agent. Pharm Res (1994) 0.87
In vitro cytotoxicity of poly(amidoamine)s: relevance to DNA delivery. Biochim Biophys Acta (1999) 0.87
Microviscosity and drug release from topical gel formulations. Pharm Res (1986) 0.87
An in vitro study of diamorphine permeation through premature human neonatal skin. Pharm Res (1993) 0.87
Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev (2001) 0.87
Targeting of colloidal particles to the bone marrow. Life Sci (1987) 0.87
Development of a novel nasal nicotine formulation comprising an optimal pulsatile and sustained plasma nicotine profile for smoking cessation. J Control Release (2002) 0.87
Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci (2006) 0.87
Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine (1989) 0.86
The effect of oils on the lymphatic absorption of DDT. J Pharm Pharmacol (1982) 0.86
Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother (1993) 0.86
Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine (2003) 0.86
Polymeric lamellar substrate particles for intranasal vaccination. Adv Drug Deliv Rev (2001) 0.86
Do recurrences after paraesophageal hernia repair matter? : Ten-year follow-up after laparoscopic repair. Surg Endosc (2007) 0.86
Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine (1999) 0.85
The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations. J Pharm Pharmacol (1985) 0.85
Dextran cross-linked gelatin microspheres as a drug delivery system. Eur J Pharm Biopharm (1999) 0.85
Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials (1987) 0.85
Determination of thermodynamics of the methylene group in solutions of drug molecules. J Pharm Pharmacol (1972) 0.85
The distribution of protein associated with poly(DL-lactide co-glycolide) microparticles and its degradation in simulated body fluids. J Control Release (1998) 0.84
Some priorities in maximizing access to and quality of contraceptive services. Adv Contracept (1996) 0.84
Antigenic variation of the bovine ephemeral fever virus glycoprotein. Arch Virol (1992) 0.84
Effect of colloidal association on the measured activity of alkylbenzyldimethylammonium chlorides against Pseudomonas aeruginosa. J Med Chem (1977) 0.84